

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
3 March 2005 (03.03.2005)

PCT

(10) International Publication Number
WO 2005/019792 A2

- (51) International Patent Classification⁷: **G01N**
- (21) International Application Number:
PCT/IB2004/002720
- (22) International Filing Date: 21 August 2004 (21.08.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/496,884 21 August 2003 (21.08.2003) US
- (71) Applicant (for all designated States except US): **McGILL UNIVERSITY** [CA/CA]; 845 Sherbrooke Street West, Montreal, Québec H3A 2T5 (CA).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **KOSKI, Kristine, G.** [US/CA]; 62 Fifth Avenue, Pointe Claire, Québec H9S 5E1 (CA). **BURNS, David, H.** [US/CA]; 4753 St-André Street, Montreal, Québec H2J 2Z9 (CA).
- (74) Agent: **OGILVY RENAULT?**; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND APPARATUS FOR ANALYZING AMNIOTIC FLUID



(57) Abstract: Methods and spectra for monitoring fetal growth and predicting birth weight of an infant prior to birth are provided wherein one or more selected biological markers are measured in a sample of amniotic fluid obtained from a pregnant woman. Levels of the selected biochemical markers and/or spectra correlate with one or more medical conditions, such as fetal growth and birth weight of the infant, and gestational diabetes. A measurement probe for in situ measurement can be used safely and repeatedly. Monitoring and/or treatment of maternal and fetal health is also provided.